Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Semnur Pharmaceuticals, Inc.
Palo Alto, California, United Statessemnurpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Semnur has completed a Phase 3 trial for SP-102 (SEMDEXA™), which met primary and important key secondary endpoints. The treatment decreased pain intensity for over a month in sciatica patients and resulted in statistically significant and clinically meaningful improvement in the disability index score while maintaining safety comparable to placebo[3].
- Therapeutic areas
- Neurology
- Modalities
- Injectable corticosteroid gel formulationNon-opioid pain therapies
- Industry
- Biotech
02
Partnerships
Denali Capital Acquisition Corp. (for SPAC merger)
Beyond the preview
Go deeper on Semnur Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Semnur Pharmaceuticals, Inc..